tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ZBIO Stock Latest News

Strategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial Potential
RatingsStrategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial Potential
11d ago
ZBIO
Zenas BioPharma Secures $300M Funding for Obexelimab
PremiumCompany Announcements
Zenas BioPharma Secures $300M Funding for Obexelimab
12d ago
8K
ZBIO
Zenas BioPharma, Royalty Pharma enter obexelimab funding agreement
PremiumThe Fly
Zenas BioPharma, Royalty Pharma enter obexelimab funding agreement
12d ago
RPRX
ZBIO
Royalty Pharma, Zenas BioPharma enter into obexelimab funding agreement
PremiumThe Fly
Royalty Pharma, Zenas BioPharma enter into obexelimab funding agreement
12d ago
RPRX
ZBIO
Buy Rating Affirmed for Zenas BioPharma: Promising Developments in Obexelimab Platform Drive Confidence
PremiumRatings
Buy Rating Affirmed for Zenas BioPharma: Promising Developments in Obexelimab Platform Drive Confidence
1M ago
ZBIO
Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit
PremiumCompany AnnouncementsZenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit
1M ago
ZBIO
Zenas BioPharma Reports Q2 2025 Financial Results
Premium
Company Announcements
Zenas BioPharma Reports Q2 2025 Financial Results
1M ago
ZBIO
Zenas BioPharma’s Growth Potential: Key Trials and Strategic Positioning Drive Buy Rating
Premium
Ratings
Zenas BioPharma’s Growth Potential: Key Trials and Strategic Positioning Drive Buy Rating
1M ago
ZBIO
Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last year
PremiumThe Fly
Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last year
1M ago
ZBIO
Zenas BioPharma expects cash to fund operations into Q4 of 2026
PremiumThe Fly
Zenas BioPharma expects cash to fund operations into Q4 of 2026
1M ago
ZBIO
Sixteen new option listings on July 23rd
PremiumThe Fly
Sixteen new option listings on July 23rd
2M ago
RAL
SMU
Promising Future for Zenas BioPharma: Buy Rating Backed by Unique Product Advantage and Strong Pipeline Developments
PremiumRatings
Promising Future for Zenas BioPharma: Buy Rating Backed by Unique Product Advantage and Strong Pipeline Developments
2M ago
ZBIO
Zenas BioPharma assumed with an Overweight at Morgan Stanley
PremiumThe FlyZenas BioPharma assumed with an Overweight at Morgan Stanley
2M ago
ZBIO
Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma
Premium
Ratings
Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma
2M ago
ZBIO
Zenas BioPharma Announces Board Changes at Annual Meeting
Premium
Company Announcements
Zenas BioPharma Announces Board Changes at Annual Meeting
3M ago
8K
ZBIO
Zenas BioPharma to Present at Jefferies Conference
PremiumCompany Announcements
Zenas BioPharma to Present at Jefferies Conference
3M ago
8K
ZBIO
Zenas BioPharma Reports Q1 2025 Financial Results
PremiumCompany Announcements
Zenas BioPharma Reports Q1 2025 Financial Results
4M ago
ZBIO
Zenas BioPharma’s Promising Autoimmune Pipeline and Obexelimab’s Competitive Edge Drive Buy Rating
PremiumRatings
Zenas BioPharma’s Promising Autoimmune Pipeline and Obexelimab’s Competitive Edge Drive Buy Rating
4M ago
ZBIO
Zenas BioPharma reports Q1 EPS (80c) vs ($17.89) last year
PremiumThe Fly
Zenas BioPharma reports Q1 EPS (80c) vs ($17.89) last year
4M ago
ZBIO
Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP Before June 16, 2025 to Discuss Your Rights – ZBIO
PremiumClass ActionZenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP Before June 16, 2025 to Discuss Your Rights – ZBIO
5M ago
ZBIO
Zenas BioPharma appoints Haley Laken as CSO
Premium
The Fly
Zenas BioPharma appoints Haley Laken as CSO
5M ago
ZBIO
Wedbush bullish on Zenas BioPharma, initiates with an Outperform
Premium
The Fly
Wedbush bullish on Zenas BioPharma, initiates with an Outperform
6M ago
ZBIO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >